Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT
Go back to Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.89 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.89 | 52 Week High | $108.63 | |||
| Open | $150.89 | 52 Week Low | $71.39 | |||
| Day High | $150.89 | P/E | 83.36 | |||
| Day Low | $150.89 | EPS | $1.81 | |||
| Volume | 4,576 | |||||
| S&P DEP RECEIPTS (NYSE: SPY) | Delayed: 762.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $762.60 | 52 Week High | $219.60 | |||
| Open | $762.60 | 52 Week Low | $181.02 | |||
| Day High | $762.60 | P/E | N/A | |||
| Day Low | $762.60 | EPS | $0.00 | |||
| Volume | 344,116 | |||||
